Genetics and Sensorineural Pathophysiology

2025 Activity indicators

8 competitive national public projects: ISCIII, MINECO/MICINN, CIBERER
2 private projects led
1 competitive HR contract
7 publications
IF: 22.5
Publications in Q1: 4 (57%)
Publications in D1: 1 (14%)
1 award
Evaluators of scientific projects in national institutions: 5 researchers
Editorial committee members: 2 PIs
Several panels developed at IRYCIS for genetic diagnostics in use at the Ramón y Cajal University Hospital
1 visitor hosted and +1 month stay:
- Foundation for Research at the University Hospital La Fe

Participation in the DFNB9 gene therapy clinical trial for hearing loss, led by Dr. Rubén Polo. Collaboration between the Otolaryngology Department and the Genetics and Neurosensory Pathophysiology research group at IRYCIS.
IRYCIS, along with the Ramón y Cajal University Hospital and the University Clinical Hospital of Santiago (CHUS) in Galicia, leads the CRINGENES Neonatal Genomic Screening Program; a pilot project for neonatal genomic screening in Spain, launched in 2025, which uses advanced genetic sequencing to detect more than 300 rare diseases in newborns at an early stage.
Participation in the OMICSPACE Sectoral Data Program. A pioneering technological platform in Spain designed to integrate genomic, clinical, and biobank data from multiple healthcare institutions without the need for physical centralization of information.
Director of the Master's Program in Bioinformatics at Alfonso X el Sabio University (UAX).
Participation in the series of conferences organized by Diariofarma: 10 topics that will shape the future of healthcare.